The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Dyania Health; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Jun Yin
No Relationships to Disclose
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte; Janssen Oncology; Nektar
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck Sharp & Dohme (Inst)
 
Rohit K. Jain
Honoraria - Alphasights (I)
Consulting or Advisory Role - EMD Serono; Gilead Sciences; Pfizer; Seattle Genetics/Astellas; Taiho Oncology (I)
Speakers' Bureau - Seattle Genetics/Astellas
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; EMD Serono; Infinity Pharmaceuticals; Merck; Myovant Sciences; Pfizer; Pfizer/Astellas; Propella Therapeutics; Tavanta Therapeutics; Veru
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Seagen (Inst)
 
Jeremy Paul Cetnar
No Relationships to Disclose
 
Debasish Sundi
Consulting or Advisory Role - Arquer Diagnostics; CG Oncology; Janssen
 
Benjamin Adam Gartrell
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Colin M Sievers
No Relationships to Disclose
 
Noah M. Hahn
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; Incyte; Janssen; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Principa Biopharma; Seattle Genetics/Astellas; Taris BioMedical; Trans Med
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst)
 
Michael Anthony Carducci
Consulting or Advisory Role - Exelixis; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); pfizer (Inst)